StonvexLoading…
StonvexStonvexStonvexCore line items from AMRZ's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.18B | $11.81B | $8.98B | $5.30B |
Operating Income | $-76.00M | $1.91B | $1.43B | $653.00M |
Net Income | $-116.00M | $1.19B | $887.00M | $342.00M |
EPS (Diluted) | $-0.21 | $2.14 | $1.60 | $0.62 |
Total Assets | $24.27B | $24.25B | $24.04B | $23.78B |
Total Liabilities | $11.18B | $10.99B | $11.14B | $11.35B |
Cash & Equivalents | $1.10B | $1.92B | $826.00M | $601.00M |
Free Cash Flow OCF − CapEx | $-1.17B | $1.42B | $-227.00M | $-896.00M |
Shares Outstanding | 553.52M | 553.08M | 553.08M | 553.08M |